PremiumRatingsPromising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating Promising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success PremiumThe FlyExelixis price target raised to $56 from $45 at Citi Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects Exelixis price target raised to $44 from $38 at TD Cowen PremiumThe FlyExelixis price target raised to $46 from $41 at Citizens JMP Exelixis: Strong Financial Performance and Market Position Justify Buy Rating Exelixis Reports Strong Q1 2025 Financial Performance 
